誉衡药业(002437) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was CNY 565,496,071.70, a decrease of 11.11% compared to the same period last year[4] - Net profit attributable to shareholders increased by 86.86% to CNY 109,341,035.92 for Q3 2025[4] - The basic earnings per share rose by 78.49% to CNY 0.0498 in Q3 2025[4] - Total operating revenue for the current period is ¥1,664,997,338.49, a decrease of 10.36% from ¥1,857,506,712.57 in the previous period[22] - Net profit for the current period is ¥247,923,573.93, an increase of 29.36% compared to ¥191,786,315.95 in the previous period[23] - Basic earnings per share for the current period is ¥0.1111, up from ¥0.0835 in the previous period[24] Assets and Liabilities - Total assets as of September 30, 2025, reached CNY 3,029,960,091.66, reflecting a 7.25% increase from the end of the previous year[4] - Total assets amount to ¥3,029,960,091.66, an increase from ¥2,825,112,612.64 in the previous period[21] - Total liabilities are ¥852,180,333.41, slightly down from ¥852,260,332.70 in the previous period[21] - The company’s total non-current assets decreased to ¥1,880,921,737.96 from ¥1,947,918,407.46 in the previous period[21] - The company’s total equity increased to ¥2,177,779,758.25 from ¥1,972,852,279.94 in the previous period[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 308,264,860.41, an increase of 2.58%[4] - Operating cash inflow for the current period is CNY 1,936,541,711.79, down from CNY 2,184,252,323.73 in the previous period, representing a decrease of approximately 11.3%[25] - Net cash flow from operating activities is CNY 308,264,860.41, slightly up from CNY 300,502,502.62 in the previous period, indicating a growth of about 2.3%[26] - Cash inflow from investment activities significantly increased to CNY 979,014,562.57 from CNY 31,412,568.97, marking a substantial rise of approximately 3020.5%[26] - Net cash flow from investment activities is negative at CNY -328,824,664.41, compared to CNY -4,852,200.48 in the previous period, indicating a worsening situation[26] - Cash inflow from financing activities decreased to CNY 70,000,000.00 from CNY 218,213,750.00, a decline of about 67.9%[26] - Net cash flow from financing activities is CNY -20,260,190.15, an improvement from CNY -537,441,513.66 in the previous period[26] - The ending cash and cash equivalents balance is CNY 438,984,652.89, down from CNY 468,538,477.75 in the previous period, reflecting a decrease of approximately 6.5%[26] - Total cash outflow from operating activities is CNY 1,628,276,851.38, down from CNY 1,883,749,821.11, a reduction of about 13.5%[26] - Cash outflow from investment activities is CNY 1,307,839,226.98, significantly higher than CNY 36,264,769.45 in the previous period, indicating a rise of approximately 3505.5%[26] Expenses - The company experienced a 34.88% reduction in selling expenses, totaling CNY 411,395,500.83, primarily due to decreased market management costs[10] - Total operating costs for the current period are ¥1,463,760,914.56, down 13.24% from ¥1,686,482,833.11 in the previous period[22] - Research and development expenses for the current period are ¥49,714,579.12, a slight increase from ¥48,755,362.80 in the previous period[23] - The company reported a decrease in sales expenses to ¥411,395,500.83 from ¥631,722,798.46 in the previous period, reflecting a cost-cutting strategy[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 102,544, with no preferred shareholders having restored voting rights[13] - The top shareholder, Shen Zhenyu, holds 4.92% of shares, amounting to 110,490,000 shares, with 82,867,500 shares subject to lock-up[13] Government Support and Recognition - The company received government subsidies amounting to CNY 24,134,568.42, a decrease of 49.92% compared to the previous year[10] - The company received a total of 3.4629 million RMB in subsidies during the reporting period, including 500,000 RMB for project support[16] - The company was awarded the "2025 China CDMO Ranking TOP20" at the CMC-CHINA Pharmaceutical Expo[17] - The company’s subsidiary received recognition as an innovative small and medium-sized enterprise by the Guangdong Provincial Department of Industry and Information Technology[17] Product Development - The company has six products that have obtained drug registration certificates, covering various therapeutic areas[16] - The company’s subsidiary, Harbin Yuheng Pharmaceutical, has passed consistency evaluations for two products in September 2025[16] Governance - The company has canceled the supervisory board, achieving a smooth transition in governance structure[17]